Datasets of YY1 expression in rheumatoid arthritis patients

The data presented in this article are related to the research article entitled “A critical role of transcription factor YY1 in rheumatoid arthritis by regulation of interleukin-6” (J. Lin, Y. He, J. Chen, Z. Zeng, B. Yang, Q. Ou, 2016) [1]. The article describes YY1 overexpression is specific for RA, but not for SLE, SS, DM or MCTD. In early RA, YY1 expression is also increased. In asymptomatic subjects with RF or ACPA positive who have high risk for developing RA, the YY1 expression is not increased obviously. Moreover, YY1 expression is positively correlated with serum CRP or ESR. In RA patients treated with anti-IL-6R monoclonal Ab tocilizumab, there is no significant difference in YY1 expression after IL-6 blocking therapy.


a b s t r a c t
The data presented in this article are related to the research article entitled "A critical role of transcription factor YY1 in rheumatoid arthritis by regulation of interleukin-6" (J. Lin, Y. He, J. Chen, Z. Zeng, B. Yang, Q. Ou, 2016) [1]. The article describes YY1 overexpression is specific for RA, but not for SLE, SS, DM or MCTD. In early RA, YY1 expression is also increased. In asymptomatic subjects with RF or ACPA positive who have high risk for developing RA, the YY1 expression is not increased obviously. Moreover, YY1 expression is positively correlated with serum CRP or ESR. In RA patients treated with anti-IL-6R monoclonal Ab tocilizumab, there is no significant difference in YY1 expression after IL- 6

Value of the data
These data can be compared to other scientific data addressing the role of YY1 in other disease. These data provide insight into the function of YY1 in IL-6 production which can be of value for research groups from related fields.
These data allow other researchers to extend the role of YY1 in RA study.

Data
Data describes YY1 expression in RA, SLE, SS, DM and MCTD patients. The data show YY1 is overexpressed in RA, but not in SLE, SS, DM or MCTD patients (Fig. 1). YY1 expression is also increased in early RA compared to healthy control ( Fig. 2A), however, YY1 expression in asymptomatic subjects with RF or ACPA positive is not increased significantly (Fig. 2B). Furthermore, YY1 expression is positively correlated with serum CRP or ESR in RA (Fig. 3). However, in RA patients treated with anti-IL-6R monoclonal Ab tocilizumab, the YY1 expression after IL-6 blocking therapy is not increased significantly (Fig. 4).

Patients
20 patients with systemic lupus erythematosus (SLE) fulfilled the 1997 revised American College of Rheumatology criteria [2], 10 patients with Sjogren's syndrome (SS) fulfilled the American-European Group Criteria [3], 10 patients with dermatomyositis (DM) fulfilled criteria described by Medsger [4],  8 patients with mixed connective tissue disease (MCTD) fulfilled the classification criteria described by Alarcon-Segovia [5] were enrolled for the study. Peripheral blood mononuclear cells (PBMC) from the patients was isolated by Ficoll. PBMC from early RA patients and asymptomatic subjects with RF or ACPA positive, PBMC from 6 RA patients before and after treated with tocilizumab (TCZ) for two months were also collected. All the PBMC collected was for detection of YY1 expression. Study protocols were approved by the Institutional Medical Ethics Review Board of the First Affiliated Hospital of Fujian Medical University, Fuzhou, China.

Real-time PCR analysis
Total RNA was extracted from PBMC cells, and real-time PCR was performed as previously described by us [6,7]. The primers used in this study was as described by us [1].

Statistical analysis
Differences between groups was analyzed by unpaired Student's t-test. Correlation analyses was done by Microsoft Excel. For all statistical analyses, P values less than 0.05 was considered statistically significant. All statistical analyses were performed using GraphPad Prism 5.0 (GraphPad Software, San Diego, CA).

Acknowledgements
This work was supported by grants from National Natural Science Foundation of China, China (81401340, 81300073) and Youth Foundation of Fujian Provincial Health and Family Planning Commission (2014-1-52).

Transparency document. Supporting information
Transparency data associated with this article can be found in the online version at http://dx.doi. org/10.1016/j.dib.2016.11.046.